Aclaris shares halved after mid-stage skin disorder fail
A Pennsylvania biotech missed the mark on multiple fronts in a mid-stage trial — and investors are not happy.
Aclaris Therapeutics reported Monday that its candidate for moderate to severe hidradenitis suppurativa (HS) missed primary and secondary efficacy endpoints in a Phase IIa trial. Shares of $ACRS fell more than 50% after the Monday morning bell.
The placebo-controlled trial, examining the oral MK2 inhibitor zunsemetinib in 95 patients randomized 1-to-1, failed to meet the primary endpoint of a change in baseline of inflammatory nodule/abscess count (AN). Patients in the active arm took a 50 mg dose twice a day for 12 weeks. The study also failed to meet secondary efficacy endpoints, including the percentage of patients achieving HiSCR-50 — an endpoint where patients see a 50% reduction in the total number of abscesses and nodules.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.